Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| InMed Pharmaceuticals Inc.INM · Entity 8139 | Chief Financial Officer | December 19, 2025 | December 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
InMed Pharmaceuticals Inc.
Report date December 19, 2025 · Filed December 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2030-12-18 | Direct | 24,250 |
Reported balance
After 2025-12-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-19 · Grant · Acquired 18,000 · Balance 24,250 F1: The options were granted on 12/19/2025 and will vest in equal installments monthly, in arrears, over 36 months (1/36 per month) |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on 12/19/2025 and will vest in equal installments monthly, in arrears, over 36 months (1/36 per month)
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 19, 2025 Filed Dec 19, 2025 11:41 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001213900-25-123635 · ownership.xml · derivative · entry 1 Jagpal Netta · CIK 0002013468 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,250 Underlying: Common shares · 18,000 shares Expires 2030-12-18 F1 · derivative.exercise_date: The options were granted on 12/19/2025 and will vest in equal installments monthly, in arrears, over 36 months (1/36 per month) Read SEC document |
| December 20, 2024 Filed Dec 23, 2024 09:26 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001213900-24-111568 · ownership.xml · derivative · entry 1 Jagpal Netta · CIK 0002013468 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 Underlying: Common shares · 3,750 shares Expires 2029-12-19 F1 · derivative.exercise_date: The options were granted on 12/20/2024 and will vest in equal installments monthly over 36 months (1/36 per month). F2 · balance_after: On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.